Extended data
Sinopharm Holdings is the core enterprise of China Pharmaceutical Group Corporation (No.199 of the Fortune 500), which was established in June 2003 and listed in Hongkong in September 2009 (0 1099. HK)。 Since its establishment more than ten years ago, it has continuously expanded its business scale, improved its business quality and increased its profitability. Now, it has developed into a leading distributor and retailer of drugs and health products in China, and a leading supply chain service provider.
Since 2005, it has been ranked first in the sales of pharmaceutical commercial enterprises in China. 20 1 1 was awarded the first enterprise in China whose pharmaceutical circulation business exceeded 100 billion yuan. In 20 16, the revenue was 258.388 billion yuan, and the sales growth rate continuously led the industry average. The profit growth rate has greatly exceeded the sales growth rate for three consecutive years, and the expense ratio is the lowest in history since listing. 20 17 years, ranked 22nd in Fortune China 500. By the end of 2065438+June 2007, the company had a registered capital of 2.767 billion yuan, total assets of 173504 million yuan and 56,000 employees.
At present, Sinopharm Holdings has 480 subsidiaries (including Sinopharm and Sinopharm), and the drug distribution network covers 3 1 province (city, district) and 2 14 cities in 335 cities above the prefecture level. It has built four hub levels in Beijing, Shanghai, Xi 'an and Guangzhou, 38 provincial levels, 24 retail stores and 654,300 retail stores.
Around the core strategy of "wholesale and retail integration", Sinopharm Holdings has vigorously developed the retail diagnosis and treatment business. Guo Da Pharmaceutical Co., Ltd., a subsidiary of Sinopharm, is the largest drug retail operator in China. China Online, a subsidiary of Sinopharm Health Online (20 16), ranks first in drug sales, and has completed Series A financing of 654.38+200 million yuan.
It has formed an online and offline parallel drug retail chain network with stores all over the country. At present, there are 4 106 retail pharmacies, including 3,693 national large pharmacies and 4 13 retail pharmacies operated by distribution subsidiaries. The company actively builds the second retail brand SPS+ professional pharmacy, and has opened more than 30 pharmacies at present.
Sinopharm Medical Devices Co., Ltd., a subsidiary of Sinopharm Holdings, is a comprehensive medical device service operator integrating product cooperative research and development, sales agency, logistics distribution and after-sales service. Focus on the overall hospital service, integrate various business models, provide customers with one-stop overall solutions and diversified value-added services, and strive to build a comprehensive service platform for medical device supply chain.
Sinopharm Chemical Reagents Co., Ltd., a subsidiary of Sinopharm Holdings, is the first professional company in China to operate chemical reagents and glass instruments. China is a professional manufacturer and distributor of large-scale chemical reagents, experimental consumables, instruments and equipment, experimental furniture and other products. The products are applied in biotechnology, environmental testing, drug research and development, educational experiments and other fields. It owns Shanghai famous trademarks such as "Shanghai Test" and "Wokai" and Shanghai famous brand products.
Sinopharm Holdings (China) Financial Leasing Co., Ltd., a subsidiary of Sinopharm Holdings, takes financial leasing business as its core, and also engages in comprehensive business such as commercial factoring and investment, providing customers with all-round financial services such as investment consulting, financial consulting, management consulting, PPP and asset management. Comprehensive layout of the medical and health industry, covering the production, circulation, retail and medical terminals of the medical and health industry chain.
Sinopharm Holdings has long undertaken the task of national drug reserve and emergency supply. At critical moments such as SARS in 2003, severe snowstorm and Wenchuan earthquake in southern China in 2008, Yushu earthquake on 20 10, Ya 'an earthquake on 20 13, Wuhan flood on 20 16 and Jiuzhaigou earthquake on 20 17, Sichuan, Sinopharm Holdings all fulfilled its obligations.
Facing the new situation of global pharmaceutical economy industry, Sinopharm Holdings will stand at a new historical starting point, take the opportunity of deepening the reform of mixed ownership, take innovation as the engine, take scientific and technological innovation as the starting point, apply Internet technology, and focus on the core strategy of "wholesale and retail integration" to vigorously develop innovative value-added services such as equipment, cold chain, hospital medical services, diagnosis and treatment, pharmaceutical e-commerce, financial services and health management, and constantly promote the company's transformation from a traditional service-oriented enterprise to a scientific and technological service-oriented enterprise.
Enterprise transformation, building a "smart medical service ecosystem", becoming an excellent global medical and health service provider, and constantly creating greater value for human health and a better life.
References:
Sinopharm Holdings official website-company profile